Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition)
Juxian Sun,Rongping Guo,Xinyu Bi,Mengchao Wu,Zhaoyou Tang,Wan Yee Lau,Shusen Zheng,Xuehao Wang,Jinming Yu,Xiaoping Chen,Jia Fan,Jiahong Dong,Yongjun Chen,Yunfu Cui,Chaoliu Dai,Chihua Fang,Shuang Feng,Zhili Ji,Weidong Jia,Ningyang Jia,Gong Li,Jing Li,Qiu Li,Jiangtao Li,Tingbo Liang,Lianxin Liu,Shichun Lu,Yi Lv,Yilei Mao,Yan Meng,Zhiqiang Meng,Feng Shen,Jie Shi,Huichuan Sun,Kaishan Tao,Gaojun Teng,Xuying Wan,Tianfu Wen,Liqun Wu,Jinglin Xia,Mingang Ying,Jian Zhai,Leida Zhang,Xuewen Zhang,Zhiwei Zhang,Haiping Zhao,Donghai Zheng,Xuting Zhi,Jie Zhou,Cuncai Zhou,Jian Zhou,Zhaochong Zeng,Kangshun Zhu,Minshan Chen,Jianqiang Cai,Shuqun Cheng
DOI: https://doi.org/10.1159/000523997
2022-01-01
Liver Cancer
Abstract:Portal vein tumor thrombus (PVTT) is very common and it plays a major role in the prognosis and clinical staging of hepatocellular carcinoma (HCC). We have published the first version of the guideline in 2016 and revised in 2018. Over the past several years, many new evidences for the treatment of PVTT become available, especially for the advent of new targeted drugs and immune checkpoint inhibitors which have further improved the prognosis of PVTT. So, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association revised the 2018 version of the guideline to adapt to the development of PVTT treatment. Future treatment strategies for HCC with PVTT in China would depend on new evidences from more future clinical trials.